EPHA1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sorafenib (SCHEMBL8218)	1.00	2/20
Dasatinib Anhydrous (SCHEMBL8226)	1.00	2/20
Dasatinib Anhydrous (SCHEMBL290515)	1.00	2/20
Regorafenib (SCHEMBL432230)	1.00	2/20
SCHEMBL620651	0.84	2/20
Sorafenib (SCHEMBL162935)	0.81	2/20
SCHEMBL432444	0.81	2/20
SCHEMBL170976	0.80	2/20
Sorafenib (SCHEMBL19322)	0.80	2/20
SCHEMBL549001	0.79	2/20
SCHEMBL548133	0.79	2/20
SCHEMBL620425	0.79	2/20
SCHEMBL170966	0.74	2/20
SCHEMBL169257	0.68	2/20
SCHEMBL545771	0.67	2/20
SCHEMBL545926	0.67	2/20
SCHEMBL545934	0.67	2/20
SCHEMBL546346	0.67	2/20
SCHEMBL619694	0.66	2/20
SCHEMBL548256	0.65	2/20

Clinical trials — most relevant to EPHA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	PHASE1/PHASE2	COMPLETED
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）	PHASE2	RECRUITING
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer	PHASE2	COMPLETED
EGF Ointment for Erlotinib Skin Lesion	PHASE2	COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer	PHASE2	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma	PHASE1	COMPLETED
Isolation of Cells From Biopsy Tissue to Aid in Kidney Repair	PHASE1	WITHDRAWN
The Role of Gene Changes in Brain Tumor Formation and Growth	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury	nan	UNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Toxins Removal and Inflammatory State modulAtion During Online Hemodiafiltration: Comparison of Two Different Dialyzers	nan	UNKNOWN
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers	nan	RECRUITING
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Reference Values of Intraepidermal Nerve Fiber Density in Children and Small Fiber Neuropathy in Neurodevelopmental Disorders	nan	COMPLETED
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children	nan	COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Study of Adrenal Gland Tumors	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EPHA1 binder may also engage these)

Protein	Name	Similarity
EPHB4	Ephrin type-B receptor 4	1.000	landscape →
O09127	—	0.997	O09127 →
Q8BYG9	—	0.996	Q8BYG9 →
Q60750	—	0.996	Q60750 →
O08644	—	0.995	O08644 →
P54761	—	0.993	P54761 →
Q03146	—	0.993	Q03146 →
TIE1	Tyrosine-protein kinase receptor Tie-1	0.992	landscape →
P55146	—	0.991	P55146 →
P52785	—	0.991	P52785 →
P0C0K6	—	0.991	P0C0K6 →
P55203	—	0.990	P55203 →
P0C0K7	—	0.990	P0C0K7 →
EPHA2	Ephrin type-A receptor 2	0.990	landscape →
Q9YI66	—	0.988	Q9YI66 →
Q03145	—	0.988	Q03145 →
Q7YR43	—	0.988	Q7YR43 →
EPHA5	Ephrin type-A receptor 5	0.987	landscape →
INSRR	Insulin receptor-related protein	0.987	landscape →
Q91735	—	0.987	Q91735 →
A0JM20	—	0.987	A0JM20 →
P51839	—	0.986	P51839 →
CSF1R	Macrophage colony-stimulating factor 1 receptor	0.986	landscape →
A0A0U1RPR8	—	0.986	A0A0U1RPR8 →
Q63474	—	0.986	Q63474 →
FGFR3	Fibroblast growth factor receptor 3	0.986	landscape →
Q61288	—	0.985	Q61288 →
P13369	—	0.985	P13369 →
P51840	—	0.985	P51840 →
EPHB6	Ephrin type-B receptor 6	0.985	landscape →